載入...
Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
Approximately 50% of HER2 positive breast cancer cases are also estrogen receptor (ER) positive. Data supports a role for close cross-talk between the ER and HER2 signaling pathways as an important contributor to the development of de novo or acquired resistance to hormone therapies. Therefore a str...
Na minha lista:
| 發表在: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6918494/ https://ncbi.nlm.nih.gov/pubmed/31897091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919894105 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|